Morgan Stanley: Oral GLP-1 Weight Loss Drug Can Propel Eli Lilly and Company to a $1 Trillion Valuation
Orally administered GLP-1 drugs are considered a holy grail of sorts in the weight loss arena, with Eli Lilly and Company's Orforglipron currently undergoing trials.